Pharvaris NV (PHVS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Pharvaris NV (PHVS)
Company Performance

Current Price

as of Oct 23, 2024

$22.21

P/E Ratio

N/A

Market Cap

$1.2B

Description

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Metrics

Overview

  • HQLeiden, ZH
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerPHVS
  • Price$22.21-0.67%

Trading Information

  • Market Cap$1.20B
  • Float33.31%
  • Average Daily Volume (1m)91,337
  • Average Daily Volume (3m)99,614
  • EPS-$2.46

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$32.01M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$36.94M
  • EV$645.99M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B3.36
Documents